Grace Webinar - Enhancing Stability and Bioavailability of Poorly Soluble APIs
Discover how silica drug delivery technology is improving the physical and chemical stability in pharmaceutical APIs.
Imagine what you could do if working with poorly soluble (BCS2) compounds was not an insurmountable issue? BCS2 compounds account for 40% of the APIs on the market today, however, 70-80% of pharmaceuticals active in the pipeline have been shelved due to solubility issues.
Hosted by C&EN’s technical contributing editor, Jeff Huber, and presented by Grace’s technical expert, Chintan Shah, this 60-minute discussion centers on a new drug delivery option that improves physical and chemical stability in pharmaceutical APIs.
In the webinar, you'll learn more about:
- Ways silica drug delivery technology is giving pharmaceutical manufacturers a new solid drug dispersion option
- Improving solubility and bioavailability by improving the physical and chemical stability in pharmaceutical APIs
- Identifying ways to improve stability of poorly soluble APIs
Featured
Active Ingredient Delivery
Accelerate the screening and development of your pharmaceutical or nutraceutical formulation with mesoporous silica gel, novel application methods, and patent-pending technologies.
SILSOL®
Our SILSOL® silica active ingredient delivery technology accelerates the screening and development of solubility, with the added benefit of doing so with compendial, scalable, and available silicas.